HPV vaccination reduces oncogenic HPV16/18 prevalence from 16% to <1% in Denmark

Denmark just dropped a mic in public health: after rolling out the HPV vaccine, the two worst cancer-causing strains (HPV16/18) plummeted from about 16% to under 1% in vaccinated women. The thread erupted into a mix of victory laps, policy beefs, and meme-y cheerleading. One crowd is popping the data champagne—“we’re below the WHO’s elimination threshold,” notes a proud Dane—while another is yelling, “Don’t forget the guys!” With bold energy, a top comment blasts years of fuzzy messaging, calling it a “massive public health failure and almost scandal” not to hammer home how the shot slashes cancers in men too.

Then came the curveball: a cautionary take that about one-third of women still carry non-vaccine high-risk HPV types. Cue debate over whether that’s a sign to expand coverage, push boosters, or just keep calm and screen on. A US expat weighed in with the secret sauce: Denmark’s digital backbone. With nationwide digital post e-boks, reminders actually reach people—no lost mail, no missing forms—while another commenter flexed Denmark’s electronic health records as the reason they can prove what works and fix what doesn’t. TL;DR: the science is winning, the comments are spicy, and the vibe is “vaccinate everyone and measure everything.”